US Patent

US11844784 — Stable pharmaceutical compositions of bendamustine

Formulation · Assigned to Slayback Pharma LLC · Expires 2042-07-29 · 16y remaining

Vulnerability score 33/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects stable, injectable pharmaceutical compositions of bendamustine suitable for intravenous administration.

USPTO Abstract

Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.

Drugs covered by this patent

Patent Metadata

Patent number
US11844784
Jurisdiction
US
Classification
Formulation
Expires
2042-07-29
Drug substance claim
No
Drug product claim
Yes
Assignee
Slayback Pharma LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.